Figure 1: Serelaxin Temporarily Decreases Blood Pressure in the Angiotensin II/L-NG-Nitroarginine Methyl Ester Experimental Model

(A) In the Chronic:post-treatment study, telemeters were implanted on day 7. Blood pressure (BP) was recorded at baseline and throughout the duration of the experiment. In each experiment, angiotensin II (AngII) (800 ng/kg/min)/L-NG-nitroarginine methyl ester (L-NAME) (30 mg/kg/day in drinking water) treatment began at day 0. On day 7, mice were randomized to serelaxin or vehicle infusion by 3-day osmotic pump. Mice were sacrificed, and cardiac and vascular parameters were measured on day 9 in the Acute:on-treatment groups and on day 28 in the Chronic:post-treatment groups. (B) Telemetric average 24-h systolic blood pressure on day 0 and daily from day 7 to day 28. (C) Systolic blood pressure changes from baseline to day 28 during AngII/L-NAME. *p = 0.028. (B, C) Two-factor repeated-measures analysis of variance with Tukey post hoc test.



Elsevier user license